Immune checkpoint inhibitor-related myasthenia gravis, myocarditis and myositis: further insights
Authors:
- 2 June 2025
- journal article
- editorial
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (6) , 1-5
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case seriesSupportive Care in Cancer, 2023
- Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravisAnnals of Clinical and Translational Neurology, 2023
- MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilationJournal of Neurology, 2021
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Unexpected Troponin Elevation in a Patient Treated with AtorvastatinThe Journal of Applied Laboratory Medicine, 2020
- Emergency presentations in patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2020
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Elevation of Cardiac Troponin T, But Not Cardiac Troponin I, in Patients With Neuromuscular DiseasesJACC, 2014